TRKC (G623R)
Sign in to save this workspaceNTRK3 · Variant type: point · HGVS: p.G623R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 98.6% | 1.4% | 84.21 |
| 2 | Ponatinib | 94.6% | 5.4% | 78.23 |
| 3 | Entrectinib | 89.9% | 10.1% | 93.69 |
| 4 | Cabozantinib | 77.5% | 22.5% | 92.73 |
| 5 | Ripretinib | 64.8% | 35.2% | 92.95 |
| 6 | Darovasertib | 64.4% | 35.6% | 96.99 |
| 7 | Tivozanib | 59.7% | 40.3% | 92.42 |
| 8 | Pralsetinib | 41.3% | 58.8% | 93.43 |
| 9 | Sorafenib | 36.1% | 63.9% | 96.72 |
| 10 | Alpelisib | 29.6% | 70.4% | 97.22 |
| 11 | Nilotinib | 27.7% | 72.3% | 96.49 |
| 12 | Defactinib | 23.2% | 76.8% | 92.68 |
| 13 | Umbralisib | 21.9% | 78.1% | 98.74 |
| 14 | Pexidartinib | 20.1% | 79.9% | 99.49 |
| 15 | Regorafenib | 19.2% | 80.8% | 95.99 |
| 16 | Apatinib | 19.0% | 81.0% | 97.73 |
| 17 | Crizotinib | 18.4% | 81.6% | 91.39 |
| 18 | Infigratinib | 17.9% | 82.1% | 98.24 |
| 19 | Selumetinib | 17.8% | 82.2% | 100.00 |
| 20 | Tenalisib | 16.0% | 84.0% | 97.98 |
| 21 | Quizartinib | 13.7% | 86.3% | 99.50 |
| 22 | Leniolisib | 12.0% | 88.0% | 100.00 |
| 23 | Capivasertib | 10.8% | 89.2% | 96.48 |
| 24 | Ribociclib | 10.5% | 89.5% | 99.25 |
| 25 | Selpercatinib | 9.7% | 90.3% | 96.72 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 98.6% | 98.9% | -0.3% |
| Ponatinib | 94.6% | 96.7% | -2.0% |
| Entrectinib | 89.9% | 98.8% | -9.0% |
| Cabozantinib | 77.5% | — | — |
| Ripretinib | 64.8% | — | — |
| Darovasertib | 64.4% | 94.5% | -30.2% |
| Tivozanib | 59.7% | 96.1% | -36.4% |
| Pralsetinib | 41.3% | 99.4% | -58.2% |
| Sorafenib | 36.1% | — | — |
| Alpelisib | 29.6% | 99.3% | -69.6% |
| Nilotinib | 27.7% | — | — |
| Defactinib | 23.2% | 91.7% | -68.4% |
| Umbralisib | 21.9% | — | — |
| Pexidartinib | 20.1% | — | — |
| Regorafenib | 19.2% | — | — |
| Apatinib | 19.0% | — | — |
| Crizotinib | 18.4% | 97.3% | -78.9% |
| Infigratinib | 17.9% | — | — |
| Selumetinib | 17.8% | — | — |
| Tenalisib | 16.0% | 98.1% | -82.0% |
| Quizartinib | 13.7% | — | — |
| Leniolisib | 12.0% | — | — |
| Capivasertib | 10.8% | — | — |
| Ribociclib | 10.5% | — | — |
| Selpercatinib | 9.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.3ms